Coronavirus Critical Care Update - January 2021
Coronavirus Critical Care Update - January 2021
The COVID-19 pandemic has prompted scientists to use adaptive research designs to evaluate potential treatments simultaneously and efficiently, increasing the likelihood that patients will receive treatments most likely to be effective for them. Lennie Derde, MD of @UMC Utrecht and Chris Seymour, MD of @UPMC join JAMA's Q&A series to discuss the latest in critical care management of COVID-19 patients and emerging treatment strategies and therapies.Originally broadcast January 13, 2021
• Earn Free CME credits by watching JAMA Livestreams and completing a brief questionnaire. Claim 0.5 credits for each video at https://ja.ma/covidqa
• Coronavirus Resource page from the JAMA Network: https://ja.ma/covidyt
• To watch all the #JAMALive Q&A's Visit: https://ja.ma/covidqaytpl
• Don't forget to hit subscribe or click https://ja.ma/subscribe
Topics discussed in this interview:
0:00 Introduction
1:07 COVID-19 in Utrecht, Netherlands
2:43 COVID-19 in Pittsburgh, PA
3:43 Current standards of care for critically ill patients
6:10 Ventilator use and intubation concerns
8:36 Interleukin-6 receptor antagonists in critically ill patients with COVID-19
10:10 Usage of sarilumab and ticilizumab
13:32 Usage of anticoagulants and concerns
16:31 Mitigating patient transfer to ICU
19:23 Convalescent plasma
19:56 Differences in defining "moderate" and "mild"
20:23 Usage of remdesivir in the US vs internationally
21:42 Outlook for critical care
24:37 Clinical progression in COVID-19
27:56 Long haulers
30:55 Projected mortality rates
33:46 Influences on long term research
---------------------------------------------------------------------------------
For more from JAMA
• https://www.jama.com
• https://www.facebook.com/JAMAJournal
• https://www.twitter.com/JAMA_Current
• https://www.linkedin.com/company/jamanetwork
Follow the JAMA Network
• https://www.jamanetwork.com
• http://www.jamanetworkaudio.com
• https://www.facebook.com/JAMANetwork
• https://www.twitter.com/JAMANetwork
• https://www.instagram.com/JAMANetwork
• https://www.pinterest.com/JAMANetwork
=====================================================================
#JAMALive #Coronavirus #COVID19 #SARSCoV2 #Pandemic
Access Non-GMO, antigen-free, FDA-approved antiviral medication formulas used in Moderna's Spikevax.
VirusTC is a retail provider of concentrated FDA-approved antiviral medication formulas. VirusTC wholesale formulas are used in Moderna products. We sell FDA-approved formulas that are compatible with university medical plans, federal insurance coverage, and many major insurance providers. Our medications are part of tailored non-invasive cancer treatment plans available at a hospital in your region. VirusTC targets problems and provides care for the symptoms. Our products and services are used by Fred Hutch Cancer Center, John Hopkins, University Hospitals, the United States Military, and professional sports. During Operation Cancer Moonshot 2023, VirusTC products killed cancer cells, increased strength, and redeveloped muscles, tissue, and brain cells after cancer treatments.